Glucose control in type 1 diabetes: From conventional to intensive therapy

Clinical Cornerstone

Volumn 1, Issue 3, 1998, Pages 29-38

  Zinman, Bernard ^a,b,c  

^a Banting Best and Diabetes Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; INSULIN;

BLOOD; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTENSIVE CARE; METABOLISM; METHODOLOGY; REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTENSIVE CARE; TREATMENT OUTCOME;

EID: 0032222611     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1098-3597(98)90016-3     Document Type: Article

References (11)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993;329:977-986.
2. Zinman B. Insulin regimens and strategies for IDDM. Diabetes Care. 1993;16(suppl 3):24-28.
3. Zinman B. The physiologic replacement of insulin. NEJM. 1989;321:363-370.
4. Home PD. Insulin therapy. In: Alberti KGMM, Zimmet P, Defronzo RA, Keen H, eds. International Textbook of Diabetes Mellitus. 2nd ed. West Sussex, England: John Wiley & Sons; 1997:899-928.
5. Johannesen J, Petersen KF, Berger M, Binder C. New insulins and other possible therapeutic approaches. Diabetologia. 1997;40:B89-B93.
6. DiMarchi RD, Chance RE, Long HB, et al. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor 1. Horm Res. 1994;41(suppl 2):93-96.
7. Holleman F, Hoekstra JBL. Insulin Lispro. NEJM. 1997;337:176-183.
8. Anderson JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46:265-270.
9. Hollemann F, Schmitt H, Rottiers R, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin Lispro. Diabetes Care. 1977;20:1827-1832.
10. Hildebrandt TP, Berger A, Volund A, Kuhl C. The subcutaneous absorption of human and bovine ultralente formulations. Diabet Med. 1985;2:355-359.
11. Zinman B, Tildesley H, Chiasson JL, et al. Insulin Lispro in CSII - results of a double-blind crossover study. Diabetes. 1997;46:440-443.